Navigation Links
Standard Hepatitis B Treatment Bested by Newcomer
Date:12/19/2007

More people respond to telbivudine compared to lamivudine, study finds

WEDNESDAY, Dec. 19 (HealthDay News) -- New research suggests that a newer medication approved for treating hepatitis B is more effective than the standard treatment, lamivudine.

Additionally, the Chinese scientists found that a significantly smaller number of people developed resistance to the newer drug, known as telbivudine (Tyzeka, Sebivo).

The study, which is published in the Dec. 20 issue of the New England Journal of Medicine, found that about 8 percent more people responded to telbivudine than lamivudine, and the risk of resistance was at least halved for people taking telbivudine.

"The multiple therapeutic choices now available for hepatitis B will enhance the ability of clinicians to maintain long-term control of HBV replication, ultimately improving clinical outcomes for more patients. These results support telbivudine as an effective therapy for patients with chronic hepatitis B," the study authors wrote.

Hepatitis B is a viral infection that attacks the liver. It can be spread in many ways, including through the exchange of blood and other bodily fluids when having sex, from sharing needles, or from a mother to her baby during pregnancy, according to the U.S. Centers for Disease Control and Prevention.

As many as one third of people infected have no symptoms, according to the CDC. When symptoms do occur, they may include jaundice, fatigue, abdominal pain, loss of appetite, nausea, vomiting and joint pain. For most people, the infection is transient, lasting no more than six months or so. However, the infection can become chronic. This occurs in only about 6 percent of people over 5 who are infected with the hepatitis B virus, in about 30 percent of infected children between 1 and 5 years old, and in as many as 90 percent of babies who are infected with the virus. Chronic hepatitis B can cause scarring of the liver, which can lead to liver cancer or liver failure.

The goal of treatment is to keep levels of the hepatitis B virus as low as possible. Even if hepatitis B levels become so low that they're undetectable, long-term treatment is still required to prevent recurrence. People with hepatitis B are tested to see if they are positive or negative for E-antigens. A positive result on the E-antigen test often indicates a stronger infection, according to the Hepatitis B Foundation. Someone with a positive result is referred to as HBeAg-positive.

While there are several treatment options available to suppress the virus, one problem is that people can develop resistance to these drugs. Two new drugs, entecavir (Baraclude) and telbivudine, have been approved to treat hepatitis B since 2005.

The current study looked at how effective telbivudine is compared to the standard first-line treatment, lamivudine.

The researchers randomly assigned 1,370 people with chronic hepatitis B to receive either 600 milligrams of telbivudine or 100 milligrams of lamivudine once daily.

After a year of treatment, 75.3 percent of HBeAg-positive people taking telbivudine showed a therapeutic response versus 67 percent of those on lamivudine. In HBeAg-negative people, 64.7 percent of those on telbivudine had a response compared to 56.3 percent of those on lamivudine.

The number of study volunteers who had undetectable levels of hepatitis B virus by the end of the treatment year were much greater for those on telbivudine. In HBeAg-positive people, 60 percent achieved undetectable levels on telbivudine versus 40.4 percent for those taking lamivudine. For HBeAg-negative study participants, telbivudine brought viral levels down to undetectable for 88.3 percent compared to 71.4 percent for lamivudine. Telbivudine also got those viral levels down about five to six weeks faster, on average, than lamivudine.

Resistance developed in 5 percent of HBeAg-positive people taking telbivudine and in 11 percent of those on lamivudine. For those who were HBeAg-negative, the rates of resistance were 2.3 percent for those on telbivudine and 10.7 percent for those on lamivudine.

According to the study's authors, both medications have a similar side effect profile, and no significant differences were found in the current study volunteers.

"Telbivudine seems to work and be safe. It seems to have shown a better therapeutic and histological response," said Dr. Marc Siegel, an internist at New York University Medical Center.

"It decreases the risk of cirrhosis. It's well-tolerated, and it prevents the progression of hepatitis B better than the standard treatment right now," said Siegel.

The study authors pointed out that telbivudine hasn't yet been compared to the other new hepatitis B medication, entecavir, in a randomized clinical trial. Entecavir has also been shown to be more effective than lamivudine and creates less resistance as well.

More information

To learn more about available treatments for hepatitis B, visit the Hepatitis B Foundation.



SOURCES: Marc Siegel, M.D., internist, New York University Medical Center, associate professor, medicine, New York University School of Medicine, and author, False Alarm: The Truth About the Epidemic of Fear; Dec. 20, 2007, New England Journal of Medicine


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
2. Standard Management Announces OTCBB Listing
3. Gastroenterology sets standards for CT colonography
4. Public Health and Need for Consistent Standards Preclude Exception for Breastfeeding Mother in National Medical Licensing Test
5. New Drug No Substitute for Standard Blood-Clot Therapy
6. National Quality Forum Issues First Consensus Standards for the Treatment of Substance Use Conditions
7. New guidelines set to improve standard of cows milk allergy care
8. Green Seal Ramps Up Environmental Standard for Household Cleaners
9. URAC CEO Testifies Before New Hampshire Legislators Regarding New URAC Standards for Pharmacy Benefit Management
10. Standard treatment for prostate cancer may encourage spread of disease
11. Health Literacy Innovations Releases New Survey on Medicaid Health Literacy Standards
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Standard Hepatitis B Treatment Bested by Newcomer 
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Consumers have taken a more active ... more emphasis on patient outcomes. ... the pharmaceutical industry have evolved beyond just providing ... are focusing on becoming more patient-oriented across their ... services that improve health. ...
(Date:6/24/2016)... June 24, 2016   Bay Area Lyme ... Dean Center for Tick Borne Illness , ... Rehabilitation, MIT Hacking Medicine, University of California, Berkeley, ... announced the five finalists of Lyme Innovation ... More than 100 scientists, clinicians, researchers, entrepreneurs, and ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
Breaking Medicine Technology: